By , Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.Gilead’s late-stage study...…By , Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.S. government trial. That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.Gilead’s late-stage study...WW…

By , ZURICH/NEW YORK (Reuters) - Swiss drugmaker Novartis AG said on Monday it will test the malaria drug hydroxychloroquine in a randomized trial to see if the much talked about medicine is actually effective against COVID-19, the illness caused by the novel coronavirus.The company hopes to have data on its efficacy by June, a lead researcher for the trial told Reuters.The decades-old generic medicine has been touted by U.S. President Donald Trump and others as a “game changer” treatment for the highly contagious respiratory illness, and the U.S. Food and Drug Administration authorized it...…By , ZURICH/NEW YORK (Reuters) - Swiss drugmaker Novartis AG said on Monday it will test the malaria drug hydroxychloroquine in a randomized trial to see if the much talked about medicine is actually effective against COVID-19, the illness caused by the novel coronavirus.The company hopes to have data on its efficacy by June, a lead researcher for the trial told Reuters.The decades-old generic medicine has been touted by U.S. President Donald Trump and others as a “game changer” treatment for the highly contagious respiratory illness, and the U.S. Food and Drug Administration authorized it...WW…

By , The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000.There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under...…By , The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline.The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000.There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under...WW…

By , , WASHINGTON (Reuters) - The head of the U.S. Centers for Disease Control and Prevention testified on Thursday on Capitol Hill that public health officials discussed coronavirus information in classified rooms on occasions “too numerous to count,” though he said the information wasn’t treated as classified.On Wednesday, Reuters reported that the White House ordered federal health officials at the Department of Health and Human Services (HHS), the nation’s premier health agency, to treat top-level coronavirus meetings as classified, citing four Trump administration officials.The...…By , , WASHINGTON (Reuters) - The head of the U.S. Centers for Disease Control and Prevention testified on Thursday on Capitol Hill that public health officials discussed coronavirus information in classified rooms on occasions “too numerous to count,” though he said the information wasn’t treated as classified.On Wednesday, Reuters reported that the White House ordered federal health officials at the Department of Health and Human Services (HHS), the nation’s premier health agency, to treat top-level coronavirus meetings as classified, citing four Trump administration officials.The...WW…

The Sweeten children, Kaden, Jackson and Emily, are seen at their home in Layton, Utah, U.S., November 8, 2020. Picture taken November 8, 2020. Tristen Sweeten/Handout via REUTERS Register now for FREE unlimited access to Reuters.comApril 16 (Reuters) - Tristen Sweeten, a 34-year-old nurse in Utah, hopes her three children will receive Moderna's COVID-19 vaccine through its pediatric clinical trial. The sooner the better, she said, for their safety and the greater goal of ending the pandemic.Angie Ankoma, a 45-year-old Black mother of four who works in philanthropy in Rhode Island, believes...…The Sweeten children, Kaden, Jackson and Emily, are seen at their home in Layton, Utah, U.S., November 8, 2020. Picture taken November 8, 2020. Tristen Sweeten/Handout via REUTERS Register now for FREE unlimited access to Reuters.comApril 16 (Reuters) - Tristen Sweeten, a 34-year-old nurse in Utah, hopes her three children will receive Moderna's COVID-19 vaccine through its pediatric clinical trial. The sooner the better, she said, for their safety and the greater goal of ending the pandemic.Angie Ankoma, a 45-year-old Black mother of four who works in philanthropy in Rhode Island, believes...WW…

By , (Reuters) - U.S. regulators on Friday said they would work quickly to authorize Johnson & Johnson’s COVID-19 vaccine for emergency use after a panel of outside advisers backed the one-shot immunization.The Food and Drug Administration is expected to decide on emergency use by Saturday for what would be the third vaccine available in the United States, and the only one that requires a single shot.The agency told J&J that “it will rapidly work toward finalization and issuance of an emergency use authorization,” the regulator said in a statement after the vote by advisers.“The...…By , (Reuters) - U.S. regulators on Friday said they would work quickly to authorize Johnson & Johnson’s COVID-19 vaccine for emergency use after a panel of outside advisers backed the one-shot immunization.The Food and Drug Administration is expected to decide on emergency use by Saturday for what would be the third vaccine available in the United States, and the only one that requires a single shot.The agency told J&J that “it will rapidly work toward finalization and issuance of an emergency use authorization,” the regulator said in a statement after the vote by advisers.“The...WW…

By (This February 17 story corrects headline and first paragraph to show the reduction was in the protective antibodies elicited by the vaccine, not the protection of the vaccine overall)Slideshow (Reuters) - A laboratory study suggests that the South African variant of the coronavirus may reduce protective antibodies elicited by the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in...…By (This February 17 story corrects headline and first paragraph to show the reduction was in the protective antibodies elicited by the vaccine, not the protection of the vaccine overall)Slideshow (Reuters) - A laboratory study suggests that the South African variant of the coronavirus may reduce protective antibodies elicited by the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in...WW…

By (This February 17 story corrects headline and first paragraph to show the reduction was in the protective antibodies elicited by the vaccine, not the protection of the vaccine overall)Slideshow (Reuters) - A laboratory study suggests that the South African variant of the coronavirus may reduce protective antibodies elicited by the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in...…By (This February 17 story corrects headline and first paragraph to show the reduction was in the protective antibodies elicited by the vaccine, not the protection of the vaccine overall)Slideshow (Reuters) - A laboratory study suggests that the South African variant of the coronavirus may reduce protective antibodies elicited by the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.The study found the vaccine was still able to neutralize the virus and there is not yet evidence from trials in...WW…

By , NEW YORK (Reuters) - Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from the Trump administration, which would reduce the industry’s profitability.The companies kept their price increases at 10% or below, and the...…By , NEW YORK (Reuters) - Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from the Trump administration, which would reduce the industry’s profitability.The companies kept their price increases at 10% or below, and the...WW…

Want to discuss? Please read our first.AdvertisementClose XAAThe U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE’s vaccine in the United States this week, a top FDA official said late on Friday.Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said at a press conference that the allergic reactions had been reported in more than one state, including in Alaska.Marks also said that a chemical called polyethylene glycol (PEG) that is an ingredient in the...…Want to discuss? Please read our first.AdvertisementClose XAAThe U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE’s vaccine in the United States this week, a top FDA official said late on Friday.Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said at a press conference that the allergic reactions had been reported in more than one state, including in Alaska.Marks also said that a chemical called polyethylene glycol (PEG) that is an ingredient in the...WW…